1-6 of 6
Howard I. Scher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation

Open Access
Deepti Mathur, Bradford P. Taylor, Walid K. Chatila, Howard I. Scher, Nikolaus Schultz, Pedram Razavi, Joao B. Xavier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 831–843.
https://doi.org/10.1158/1535-7163.MCT-21-0574
Published: 04 May 2022
View articletitled, Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
Open the PDF for Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation in another window
Includes: Supplementary data
Journal Articles

Abstract B114: Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response.

Free
Matthew S. Brown, Gregory H. Chu, Hyun Jung (Grace) Kim, Martin A. Auerbach, Cheryce Poon, Adria Vidovic, Bharath Ramakrishna, David W. Gjertson, Howard I. Scher, Jonathan G. Goldin, Matthew R. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B114.
https://doi.org/10.1158/1535-7163.TARG-11-B114
Published: 12 November 2011
View articletitled, Abstract B114: Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response.
Journal Articles

Abstract B57: Cabozantinib (XL184) reduces pain symptoms in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases: Results from a phase 2 nonrandomized expansion cohort.

Free
Ethan Basch, Antonia V. Bennett, Howard I. Scher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B57.
https://doi.org/10.1158/1535-7163.TARG-11-B57
Published: 12 November 2011
View articletitled, Abstract B57: Cabozantinib (XL184) reduces pain symptoms in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases: Results from a phase 2 nonrandomized expansion cohort.
Journal Articles

Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100

Free
Howard I. Scher, Daniel C. Danila, Tomasz M. Beer, Celestia Higano, Dana Rathkopf, Mary‐Ellen Taplin, Eleni Efstathiou, Aseem Anand, David Hung, Mohammed Hirmand, Lynn Seely, Steven M. Larson, Martin Fleisher, Charles Sawyers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): CN02-03.
https://doi.org/10.1158/1535-7163.TARG-09-CN02-03
Published: 10 December 2009
View articletitled, Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100
Journal Articles

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

Free
Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon, Lisa M. Butler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (1): 51–60.
https://doi.org/10.1158/1535-7163.MCT-06-0144
Published: 19 January 2007
View articletitled, Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Open the PDF for Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation in another window
Journal Articles

Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer

Free
Daniel E.H. Afar, Vinay Bhaskar, Eric Ibsen, Danna Breinberg, Susan M. Henshall, James G. Kench, Marija Drobnjak, Rick Powers, Melanie Wong, Ferdinand Evangelista, Chris O'Hara, David Powers, Robert B. DuBridge, Ingrid Caras, Ruth Winter, Terri Anderson, Nanette Solvason, Phillip D. Stricker, Carlos Cordon-Cardo, Howard I. Scher, John J. Grygiel, Robert L. Sutherland, Richard Murray, Vanitha Ramakrishnan, Debbie A. Law
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (8): 921–932.
https://doi.org/10.1158/1535-7163.921.3.8
Published: 06 August 2004
View articletitled, Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer
Open the PDF for Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer in another window